Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study

Figure 2

Comparison between the longest PFS on MP-guided therapy (dark grey) and PFS on last regimen on which patients progressed before MP (light grey) in 9 patients for whom this ratio was ≥1.3.